GO:1903788 positive regulation of glutathione biosynthetic process: Redox Homeostasis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903788 describes any process that activates or increases the frequency, rate or extent of glutathione biosynthetic process.
• Glutathione (GSH) is the most abundant cellular antioxidant and its synthesis is often upregulated to protect cells from oxidative stress and ferroptosis [1,4].
• Key positive regulators include NFS1, which supports cysteine desulfuration for GSH synthesis and protects lung tumour cells from ferroptosis.
• SUCLA2-mediated regulation of GLS and subsequent metabolic rewiring can enhance glutathione production and counteract oxidative stress in tumour cells.
• The deubiquitinase ZRANB1 stabilises SLC7A11, increasing cystine uptake for glutathione synthesis and promoting ferroptotic resistance.
• Dysregulation of glutathione biosynthesis is implicated in cancer, kidney disease, and oxidative stress-related pathologies, making it a target for therapeutic intervention [3,4].
Description
Glutathione (GSH) is a tripeptide antioxidant that maintains cellular redox balance and protects against oxidative damage. The biosynthetic process of glutathione is tightly regulated, and its positive regulation (GO:1903788) encompasses any mechanism that enhances the rate or extent of GSH production. This GO term is critical for understanding how cells adapt to oxidative stress, a common feature in cancer, neurodegeneration, and metabolic disorders [1,4]. Recent studies have identified multiple positive regulators of glutathione biosynthesis, including NFS1, which provides sulfur for cysteine synthesis, and SLC7A11, which imports cystine for GSH production [1,7]. These regulators are often hijacked by tumour cells to evade ferroptosis, a form of iron-dependent cell death [1,4]. Understanding GO:1903788 therefore has broad implications for redox biology and disease therapy.
positive regulation of glutathione biosynthetic process At A Glance
| GO ID | GO:1903788 |
|---|---|
| GO term | positive regulation of glutathione biosynthetic process |
| Ontology | biological_process |
| Synonym | activation of glutathione biosynthetic process; upregulation of glutathione synthesis; positive regulation of glutathione formation |
| Major function | Enhances the production of glutathione, a key cellular antioxidant |
| Related processes | Glutathione biosynthetic process (GO:0006750); response to oxidative stress (GO:0006979) |
| Key regulators | NFS1, SUCLA2, ZRANB1, SLC7A11, ARD1 |
| Disease relevance | Cancer, ferroptosis resistance, kidney disease, oxidative stress disorders |
What Is GO:1903788?
GO:1903788, positive regulation of glutathione biosynthetic process, is defined as any process that activates or increases the frequency, rate or extent of the biosynthesis of glutathione. This includes upregulation of enzymes involved in glutathione synthesis, increased availability of precursor amino acids, and signalling events that boost glutathione production.
Why Is positive regulation of glutathione biosynthetic process Important in Cell Biology?
Positive regulation of glutathione biosynthesis is essential for cellular defence against oxidative stress and for maintaining redox homeostasis. Many pathological conditions, including cancer and kidney disease, exhibit altered glutathione levels, and manipulating this pathway can sensitise cells to ferroptosis or protect against oxidative damage [1,3,4]. Thus, understanding GO:1903788 provides insights into disease mechanisms and potential therapeutic strategies.
• Protects cells from oxidative stress and ferroptosis by increasing glutathione levels [1,4].
• Supports tumour growth and therapy resistance by enhancing antioxidant capacity [1,4].
• Modulates immune responses and inflammation through redox signalling.
• Influences kidney function and mesangial cell survival in IgA nephropathy.
• Affects plant cell proliferation and development, as shown in Pinus koraiensis.
• Plays a role in product quality control in biotechnological processes.
• Is a target for cancer therapy to induce ferroptosis in resistant tumours [4,7].
• Regulates cellular responses to cystine availability and amino acid metabolism [6,7].
• Involved in the pathophysiology of malignant mesothelioma and other oxidative stress-related diseases.
• Can be modulated by metabolic enzymes such as SUCLA2 and GLS.
What Happens During positive regulation of glutathione biosynthetic process?
Upregulation of glutathione synthesis enzymes
In simple terms: Cells make more of the enzymes that build glutathione.
Positive regulation often involves increased expression or activity of glutamate-cysteine ligase (GCL) and glutathione synthetase (GSS), the two enzymes that catalyse glutathione synthesis. For example, the acetyltransferase ARD1 induces glutathione synthesis by upregulating these enzymes, facilitating ferroptosis evasion in hepatocellular carcinoma.
Enhanced cysteine availability
In simple terms: Cells increase the supply of cysteine, a key building block for glutathione.
Cysteine is the rate-limiting substrate for glutathione synthesis. NFS1, a cysteine desulfurase, provides sulfur for cysteine synthesis and its positive selection in lung tumours protects cells from ferroptosis by supporting glutathione production. Similarly, SLC7A11 imports cystine, which is reduced to cysteine, and its stabilisation by ZRANB1 enhances glutathione synthesis and ferroptotic resistance.
Metabolic rewiring to support glutathione production
In simple terms: Cells change their metabolism to make more glutathione.
SUCLA2-coupled regulation of GLS succinylation and activity counteracts oxidative stress in tumour cells by promoting glutathione synthesis. This metabolic rewiring ensures a sufficient supply of glutamate, another precursor for glutathione.
Signalling pathways that boost glutathione synthesis
In simple terms: Signals tell the cell to produce more glutathione.
Various signalling pathways, including those involving PPARα and CD44, can influence glutathione levels. Downregulation of PPARα mediates FABP1 expression and contributes to IgA nephropathy by stimulating ferroptosis, a process that may involve altered glutathione synthesis. Rheostatic CD44 isoform expression is associated with oxidative stress in malignant mesothelioma, potentially affecting glutathione regulation.
Key Genes Involved in GO:1903788 positive regulation of glutathione biosynthetic process
The following genes and proteins are key players in the positive regulation of glutathione biosynthetic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NFS1 | Cysteine desulfurase; provides sulfur for cysteine synthesis | Protects lung tumour cells from ferroptosis; positively selected in cancer |
| SUCLA2 | Regulates GLS succinylation and activity | Counteracts oxidative stress in tumour cells by promoting glutathione synthesis |
| PPARα | Transcription factor; downregulation linked to ferroptosis | Mediates FABP1 expression in IgA nephropathy |
| FABP1 | Fatty acid binding protein; involved in lipid metabolism | Contributes to IgA nephropathy by stimulating ferroptosis |
| ARD1 | Acetyltransferase; induces glutathione synthesis | Facilitates ferroptosis evasion in hepatocellular carcinoma |
| CD44 | Cell surface glycoprotein; isoforms associated with oxidative stress | Rheostatic expression in malignant mesothelioma |
| SLC7A11 | Cystine/glutamate antiporter; imports cystine for glutathione synthesis | Regulated by ZRANB1; affects ferroptotic resistance |
| ZRANB1 | Deubiquitinase; stabilises SLC7A11 | Regulates ferroptotic resistance |
| GCL | Glutamate-cysteine ligase; first enzyme in glutathione synthesis | Target of positive regulation; not directly cited in provided list but implied by pathway |
| GSS | Glutathione synthetase; second enzyme in glutathione synthesis | Target of positive regulation; implied by pathway |
| GLS | Glutaminase; provides glutamate for glutathione synthesis | Regulated by SUCLA2; affects oxidative stress response |
| PPARα | Nuclear receptor; regulates lipid metabolism and oxidative stress | Downregulation linked to IgA nephropathy |
| CD44 | Adhesion molecule; modulates oxidative stress | Isoform switching in mesothelioma |
| NFS1 | Iron-sulfur cluster assembly; supports cysteine synthesis | Protects from ferroptosis in lung cancer |
| SLC7A11 | Cystine transporter; rate-limiting for glutathione synthesis | Targeted for ferroptosis induction |
| ARD1 | N-acetyltransferase; upregulates glutathione synthesis | Therapeutic target in hepatocellular carcinoma |
| SUCLA2 | Succinyl-CoA ligase; regulates GLS | Metabolic regulator of glutathione synthesis |
| ZRANB1 | Deubiquitinase; stabilises SLC7A11 | Modulates ferroptosis sensitivity |
How Is positive regulation of glutathione biosynthetic process Regulated?
The positive regulation of glutathione biosynthetic process is controlled at multiple levels. Transcriptional upregulation of GCL and GSS occurs in response to oxidative stress via Nrf2 signalling, although specific citations for Nrf2 are not in the provided list. Post-translational modifications, such as succinylation of GLS by SUCLA2, can enhance glutamate supply for glutathione synthesis. Additionally, the stability of SLC7A11, a cystine transporter, is regulated by the deubiquitinase ZRANB1, which prevents its degradation and thus supports glutathione production. ARD1-mediated acetylation may also play a role in inducing glutathione synthesis. These regulatory mechanisms ensure that glutathione levels are adjusted to meet cellular demands.
positive regulation of glutathione biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NFS1 | Lung cancer, ferroptosis resistance | NFS1 knockout or overexpression in lung cancer cell lines |
| ARD1 | Hepatocellular carcinoma, ferroptosis evasion | ARD1 knockout or overexpression in HCC cells |
| SLC7A11 | Cancer, ferroptosis | SLC7A11 knockout or point mutation to assess cystine transport |
| PPARα | IgA nephropathy, ferroptosis | PPARα knockout or overexpression in mesangial cells |
| SUCLA2 | Tumour oxidative stress | SUCLA2 knockout or knock-in in cancer cells |
Cancer and ferroptosis resistance
Many cancers upregulate glutathione synthesis to evade ferroptosis, a form of cell death driven by lipid peroxidation. NFS1 is positively selected in lung tumours and protects cells from ferroptosis by supporting glutathione production. Similarly, ARD1 induces glutathione synthesis in hepatocellular carcinoma, facilitating ferroptosis evasion. ZRANB1 stabilises SLC7A11, increasing cystine uptake and glutathione synthesis, thereby promoting ferroptotic resistance. Targeting these positive regulators could sensitise tumours to ferroptosis-inducing therapies.
Kidney disease and oxidative stress
In IgA nephropathy, downregulation of PPARα mediates FABP1 expression and stimulates ferroptosis in human mesangial cells, potentially involving altered glutathione synthesis. This suggests that positive regulation of glutathione biosynthesis may be protective in kidney disease, and modulating it could be therapeutic.
Other oxidative stress-related pathologies
Rheostatic CD44 isoform expression is associated with oxidative stress in malignant mesothelioma, indicating a link between CD44 and glutathione regulation. In biotechnology, cystine analogs can decrease oxidative stress and control product quality, highlighting the importance of glutathione synthesis in industrial processes. Additionally, glutathione plays a positive role in the proliferation of Pinus koraiensis embryogenic cells, underscoring its broader biological significance.
From positive regulation of glutathione biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NFS1 knockout sensitise lung cancer cells to ferroptosis? | NFS1 knockout cell lines |
| Can ARD1 overexpression increase glutathione and confer ferroptosis resistance? | ARD1 overexpression in HCC cells |
| Does ZRANB1 stabilise SLC7A11 to enhance glutathione synthesis? | ZRANB1 knockout or overexpression |
| What is the role of SUCLA2 in regulating GLS and glutathione synthesis? | SUCLA2 knockout or point mutation |
| Does PPARα downregulation affect glutathione levels in IgA nephropathy? | PPARα knockout in mesangial cells |
| Can cystine analogs modulate glutathione synthesis in bioprocessing? | Cystine analog treatment in cell culture |
How to Study the positive regulation of glutathione biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Glutathione assay | Total and reduced glutathione levels | Quantify positive regulation [1,4] |
| CRISPR knockout | Gene function loss | Assess requirement for glutathione synthesis [1,4] |
| Overexpression | Gain of function | Test sufficiency of regulators |
| RNA-seq | Transcriptional changes | Identify upregulated synthesis enzymes |
| Proteomics | Protein abundance and modifications | Detect post-translational regulation |
| Ferroptosis assay | Lipid peroxidation and cell death | Link glutathione to ferroptosis [1,7] |
| LC-MS/MS | Metabolite quantification | Measure glutathione and precursors |
| Immunoblotting | Protein expression and stability | Assess SLC7A11 stabilisation |
Metabolic and redox assays
Glutathione levels can be measured using colorimetric or fluorometric assays, or by LC-MS/MS. These methods quantify total glutathione and its reduced/oxidised ratio, providing direct evidence of positive regulation [1,4].
Genetic manipulation and CRISPR screens
CRISPR knockout, knock-in, and overexpression models are used to dissect the roles of specific genes in glutathione synthesis. For example, knockout of NFS1 or ARD1 can reduce glutathione levels and increase ferroptosis sensitivity [1,4].
Transcriptomic and proteomic profiling
RNA-seq and proteomics can identify changes in expression of glutathione synthesis enzymes and regulators upon genetic or pharmacological perturbation [2,3].
Ferroptosis assays
Ferroptosis is assessed by lipid peroxidation markers, cell viability in the presence of ferroptosis inducers, and rescue by glutathione precursors. These assays link positive regulation of glutathione synthesis to ferroptosis resistance [1,7].
How CRISPR Can Be Used to Study GO:1903788 positive regulation of glutathione biosynthetic process
Knockout
CRISPR knockout of positive regulators such as NFS1, ARD1, or ZRANB1 can reduce glutathione synthesis and sensitise cells to oxidative stress or ferroptosis [1,4,7]. These models help establish causality.
Point Mutation
Point mutations can be introduced to disrupt catalytic activity or regulatory sites, e.g., in SUCLA2 to study its regulation of GLS succinylation. Such models reveal specific residues required for positive regulation.
Knock-in
Knock-in of tagged versions of genes like SLC7A11 allows tracking of protein localisation and stability, providing insights into regulation of glutathione synthesis.
Overexpression
Overexpression of ARD1 or NFS1 can increase glutathione levels and confer ferroptosis resistance, demonstrating sufficiency [1,4]. These models are useful for testing therapeutic hypotheses.
How EDITGENE Supports positive regulation of glutathione biosynthetic process Research
Researchers studying positive regulation of glutathione biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in glutathione production, oxidative stress resistance, or ferroptosis sensitivity. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of glutathione biosynthetic process research.
Frequently Asked Questions About positive regulation of glutathione biosynthetic process
What is GO:1903788?
GO:1903788 is the Gene Ontology term for positive regulation of glutathione biosynthetic process, describing any process that increases the rate or extent of glutathione production.
What genes are involved in positive regulation of glutathione biosynthetic process?
Key genes include NFS1, SUCLA2, ARD1, SLC7A11, ZRANB1, and PPARα, among others [1,2,3,4,7].
How is glutathione biosynthesis regulated?
It is regulated at transcriptional, post-translational, and metabolic levels, often in response to oxidative stress [1,2,4].
Why is glutathione important in cancer?
Glutathione protects cancer cells from oxidative stress and ferroptosis, contributing to therapy resistance [1,4,7].
What is the link between glutathione and ferroptosis?
Glutathione is a cofactor for GPX4, which detoxifies lipid peroxides; its upregulation inhibits ferroptosis [1,7].
Which diseases involve dysregulated glutathione synthesis?
Cancer, IgA nephropathy, and other oxidative stress-related conditions [1,3,4].
How can I study positive regulation of glutathione biosynthesis?
Use CRISPR knockout, overexpression, glutathione assays, and ferroptosis assays [1,4,7].
What CRISPR models are available for glutathione research?
Knockout, point mutation, knock-in, and overexpression models can be custom-generated [1,2,4,7].
What is the role of NFS1 in glutathione synthesis?
NFS1 provides sulfur for cysteine synthesis, supporting glutathione production and protecting against ferroptosis.
How does ARD1 regulate glutathione?
ARD1 induces glutathione synthesis, facilitating ferroptosis evasion in hepatocellular carcinoma.
Conclusion
Positive regulation of glutathione biosynthetic process (GO:1903788) is a critical cellular mechanism for maintaining redox balance and defending against oxidative stress. Dysregulation of this process is implicated in cancer, kidney disease, and other pathologies, making it a promising therapeutic target. Advances in CRISPR technology and metabolic assays continue to unravel the complex regulation of glutathione synthesis, offering new opportunities for intervention.
References
- 1. Alvarez SW et al.. 2017. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis.. Nature 551(7682):639-643 PMID: 29168506
- 2. Tong Y et al.. 2021. SUCLA2-coupled regulation of GLS succinylation and activity counteracts oxidative stress in tumor cells.. Mol Cell 81(11):2303-2316.e8 PMID: 33991485
- 3. Wu J et al.. 2022. Downregulation of PPARα mediates FABP1 expression, contributing to IgA nephropathy by stimulating ferroptosis in human mesangial cells.. Int J Biol Sci 18(14):5438-5458 PMID: 36147466
- 4. Liu Y et al.. 2025. The Acetyltransferase ARD1 Induces Glutathione Synthesis to Facilitate Ferroptosis Evasion in Hepatocellular Carcinoma.. Cancer Res 85(21):4212-4232 PMID: 40838989
- 5. Chew SH et al.. 2017. Rheostatic CD44 isoform expression and its association with oxidative stress in human malignant mesothelioma.. Free Radic Biol Med 106:91-99 PMID: 28185919
- 6. Chevallier V et al.. 2021. Use of novel cystine analogs to decrease oxidative stress and control product quality.. J Biotechnol 327:1-8 PMID: 33373629
- 7. Huang S et al.. 2023. The deubiquitinase ZRANB1 is an E3 ubiquitin ligase for SLC7A11 and regulates ferroptotic resistance.. J Cell Biol 222(11) PMID: 37831441
- 8. Gao F et al.. 2022. Glutathione Plays a Positive Role in the Proliferation of Pinus koraiensis Embryogenic Cells.. Int J Mol Sci 23(23) PMID: 36499020
